Tecentriq Combo Produces Disappointing Results in Advanced Ovarian Cancer Trial

Tecentriq Combo Produces Disappointing Results in Advanced Ovarian Cancer Trial
The addition of Tecentriq (atezolizumab) to first-line treatment with Avastin (bevacizumab) and chemotherapy does not significantly extend survival without disease worsening in people with newly-diagnosed advanced ovarian cancer, a recent trial shows. While the IMagyn050 Phase 3 trial (NCT03038100) failed to meet one of its primary endpoints, researchers are gathering more data to determine whether the Tecentriq combo increases survival times, either in the overall trial population or in a subgroup whose cancers are positive for the PD-L1 protein. “Ovarian cancer remains one of the most aggressive cancers and is difficult to treat in its advanced stages,” Levi Garraway, MD, PhD, Roche’s chief medical officer, said in a press release“While we are disappointed by these results, we remain committed to improving outcomes for women living with this disease and are pleased that Avastin remains a key componen
Subscribe or to access all post and page content.